Perihilar bile duct cancer, commonly known as Klatskin tumor, is a rare but serious form of cholangiocarcinoma that arises at the confluence of the right and left hepatic bile ducts. It is the most frequent type of bile duct cancer and is often challenging to diagnose early because initial symptoms, such as mild jaundice, pruritus, or vague abdominal discomfort, may be subtle or nonspecific. The cancer is staged using the TNM system, which reflects tumor size, local invasion, lymph node involvement, and distant metastasis. Stage 0 (carcinoma in situ) is confined to the bile duct lining without invasion of surrounding tissue. Stage I indicates a tumor localized to the bile duct itself without spread to adjacent structures. Stage II occurs when the tumor invades nearby tissues or blood vessels but has not yet reached lymph nodes. Stage III is defined by regional lymph node involvement or extension into nearby organs, significantly increasing the complexity of treatment. Stage IV represents advanced disease with metastasis to distant organs, such as the liver, lungs, or peritoneal cavity, and is associated with poor prognosis. Given its anatomical location and tendency to grow along bile ducts, perihilar bile duct cancer frequently presents at an advanced stage, making early detection, accurate staging, and a multidisciplinary treatment approach critical for improving patient outcomes.

Risk factors for perihilar bile duct cancer include conditions and exposures that chronically affect the bile ducts, liver, or biliary system. Primary sclerosing cholangitis (PSC), a chronic inflammatory disease of the bile ducts, significantly increases the risk due to long-term tissue damage. Chronic liver diseases, including hepatitis B and C infections and cirrhosis, also predispose individuals to cholangiocarcinoma by promoting a pro-inflammatory and fibrotic environment. Choledochal cysts, which are congenital malformations of the bile ducts, can lead to bile stasis and chronic inflammation, raising cancer risk. Parasitic infections, particularly liver flukes common in parts of Southeast Asia, induce prolonged bile duct irritation, contributing to malignant transformation. Historical exposure to toxins such as Thorotrast, a radiographic contrast agent, has been linked to bile duct cancer. Additionally, metabolic conditions like obesity and diabetes may further increase risk by promoting chronic inflammation and oxidative stress in the liver and biliary system. Collectively, these factors highlight the role of chronic biliary injury, inflammation, and metabolic stress in the development of perihilar bile duct cancer.

Perihilar bile duct cancer, or Klatskin tumor, typically manifests through a constellation of symptoms primarily caused by bile duct obstruction and local tumor effects, though early stages may be asymptomatic or subtle. Jaundice, the most common presenting symptom, results from accumulation of bilirubin in the bloodstream when the tumor blocks bile flow, leading to yellowing of the skin and sclera. Alongside jaundice, patients often experience dark-colored urine due to excess bilirubin excreted via the kidneys, and pale or clay-colored stools because bile pigments fail to reach the intestines. Pruritus (intense itching) is another hallmark symptom, caused by deposition of bile salts in the skin. Local tumor effects can produce right upper quadrant abdominal pain, which may be dull or intermittent, sometimes radiating to the back or shoulder, reflecting stretching or inflammation of biliary tissues. Systemic manifestations such as unexplained weight loss, fatigue, and general malaise often appear as the disease progresses, reflecting metabolic disturbances and the catabolic effects of malignancy. If the bile ducts become secondarily infected, fever, chills, and rigors may develop, signaling cholangitis, which can be life-threatening if untreated. Some patients may also report loss of appetite and nausea, further contributing to weight loss. Because these symptoms overlap with other hepatobiliary diseases, careful clinical evaluation is essential, particularly in individuals with known risk factors such as primary sclerosing cholangitis, chronic liver disease, or choledochal cysts. Early recognition of jaundice, pruritus, and changes in stool or urine color can prompt timely imaging and diagnostic workup, improving the chances of successful intervention.

Diagnosis of perihilar bile duct cancer involves a combination of imaging, tissue sampling, and laboratory evaluation to confirm malignancy and assess the extent of disease. Imaging tests are usually the first step: ultrasound can detect bile duct obstruction and biliary dilation, while CT scans and MRI with MRCP (magnetic resonance cholangiopancreatography) provide detailed visualization of the tumor, its relationship with hepatic ducts, vascular structures, and potential local or distant spread. Endoscopic retrograde cholangiopancreatography (ERCP) allows direct imaging of the bile ducts and enables brush cytology to collect cells for analysis. When ERCP is not feasible, percutaneous transhepatic cholangiography (PTC) offers an alternative route for imaging and biopsy. Definitive diagnosis is established through tissue sampling, either via brush cytology during ERCP or image-guided needle biopsy, which allows histopathological confirmation. Blood tests support the diagnostic process and help monitor disease: liver function tests (LFTs) typically show elevated bilirubin and alkaline phosphatase due to bile duct obstruction, while tumor markers such as CA 19-9 and CEA are not diagnostic alone but can assist in disease monitoring and response to therapy. Combining these diagnostic modalities ensures accurate staging, guides treatment planning, and improves the likelihood of effective management.

Treatment of perihilar bile duct cancer depends on tumor stage, location, and patient health, with the primary goal being curative resection when feasible. Surgery offers the best chance for cure and typically involves liver resection (partial hepatectomy) to remove the tumor along with affected bile ducts, followed by hepatobiliary reconstruction to restore bile flow. In select early-stage patients, liver transplantation may be considered. Radiation therapy either external beam radiation or brachytherapy can be used postoperatively to eliminate residual cancer cells or for local control in unresectable cases. Chemotherapy, most commonly a combination of gemcitabine and cisplatin, is indicated for advanced or metastatic disease and can also be given as adjuvant therapy after surgery to reduce recurrence risk. Emerging targeted therapies and immunotherapies are being explored, including IDH1 inhibitors, FGFR2 fusion-targeted drugs like pemigatinib, and checkpoint inhibitors for tumors with high microsatellite instability. For patients with inoperable tumors, palliative measures such as biliary stent placement help relieve jaundice, while palliative radiation or chemotherapy may control tumor progression and alleviate symptoms, improving quality of life.

Risk reduction for perihilar bile duct cancer focuses on minimizing chronic liver and bile duct injury as well as modifiable lifestyle risks. Managing liver diseases such as hepatitis B, hepatitis C, and primary sclerosing cholangitis is crucial, as these conditions increase long-term inflammation and cancer risk. In regions where liver flukes are endemic, thoroughly cooking freshwater fish helps prevent parasitic infections that can damage the bile ducts. Limiting alcohol consumption and avoiding tobacco reduces cumulative liver injury and systemic carcinogenic exposure. Maintaining a healthy diet and regular exercise helps control obesity and metabolic disorders, which may indirectly lower bile duct cancer risk by reducing systemic inflammation and promoting overall liver health.

Current research on perihilar bile duct cancer is focused on enhancing treatment and patient outcomes through improved chemotherapy regimens, immunotherapy with PD-1/PD-L1 inhibitors, gene-targeted therapies like IDH1 inhibitors, and minimally invasive surgical techniques to improve recovery and reduce complications.

1. Is perihilar bile duct cancer curable? It is potentially curable only in early-stage cases when complete surgical removal is possible. 2. What is the survival rate? Localized (resectable) tumors have a 5-year survival of 2040%, while advanced, untreated cases have a median survival of less than one year. 3. Can this cancer be detected early? Early detection is difficult due to vague symptoms; high-risk individuals may benefit from routine imaging and surveillance. 4. What happens if surgery isnt an option? Palliative care including biliary drainage, chemotherapy, and radiation can relieve symptoms and improve quality of life. 5. What are the common symptoms? Symptoms include jaundice, dark urine, pale stools, right upper quadrant abdominal pain, pruritus (itchy skin), unexplained weight loss, fatigue, and, if infection occurs, fever or chills.